Clinical Trial Update: Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma [Phase 4]

View source ↗

Summary

This document reports a Phase 4 clinical trial of anti-CD19:TCRζ CAR-T cells for CD19-positive B-cell lymphoma. The current status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Anti-CD19:TCRζ CAR-T cells

Snippet

Sponsor: jiangjingting | Conditions: Lymphoma, B Cell | Phase 4 | Status: UNKNOWN